What is the appropriate treatment for a serum 25‑hydroxyvitamin D level of 18 ng/mL?

Treatment for Vitamin D Level of 18 ng/mL

For a serum 25-hydroxyvitamin D level of 18 ng/mL, prescribe 50,000 IU of vitamin D₃ (cholecalciferol) once weekly for 8 weeks, followed by maintenance therapy with 1,500–2,000 IU daily to sustain levels ≥30 ng/mL. 1, 2

Classification and Target

• A level of 18 ng/mL is classified as vitamin D deficiency (defined as <20 ng/mL) and requires active repletion 1, 2
• The therapeutic target is ≥30 ng/mL (≥75 nmol/L), the threshold below which secondary hyperparathyroidism becomes increasingly common and musculoskeletal health is compromised 1, 2

Loading Phase: Two Equivalent Options

Option 1: Weekly High-Dose (Preferred for Adherence)

• 50,000 IU vitamin D₃ once weekly for 8 weeks (total 400,000 IU) 1, 2
• This regimen corrects deficiency in >95% of patients and is the evidence-based standard endorsed by the Endocrine Society 1, 2
• Weekly dosing improves adherence for patients who prefer less frequent administration 2

Option 2: Daily High-Dose (Preferred Physiologically)

• 5,000–6,000 IU vitamin D₃ daily for 8–12 weeks 1, 2
• Daily dosing mimics physiologic cutaneous production and avoids the metabolic complications of large bolus doses 2
• It prevents excessive 24-hydroxylation that converts vitamin D to inactive metabolites 2

Formulation Selection

Strongly prefer vitamin D₃ (cholecalciferol) over vitamin D₂ (ergocalciferol) because: 1, 2

• D₃ sustains serum 25(OH)D concentrations longer, especially with intermittent dosing 1, 2
• D₃ raises serum levels approximately 1.7-fold more efficiently than D₂ at equivalent doses 1
• Many 25(OH)D assays have limited cross-reactivity with 25(OH)D₂, potentially producing spuriously low values when D₂ is used 2

Maintenance Phase

After completing the 8-week loading phase:

• Prescribe 1,500–2,000 IU vitamin D₃ daily to maintain serum 25(OH)D ≥30 ng/mL 1, 2
• Alternative maintenance: 50,000 IU every 2 weeks effectively maintains levels between 35–50 ng/mL 1

Dose Adjustments for High-Risk Populations

If the patient has obesity (BMI >30), malabsorption syndromes, or takes enzyme-inducing medications (anticonvulsants, glucocorticoids, rifampin), standard dosing will fail: 1, 2

• Loading phase: 6,000–10,000 IU daily for 8 weeks (2–3× standard dose) 1, 2
• Maintenance phase: 3,000–6,000 IU daily 1, 2
• Rationale: Adipose tissue sequesters vitamin D, and certain medications accelerate 25(OH)D catabolism, requiring higher doses to achieve target levels 1, 3

Monitoring Strategy

• Re-measure serum 25(OH)D at 3 months after initiating therapy to confirm adequate response (steady-state is reached at ~12 weeks given the 2–3 week half-life) 1, 2
• If the level remains <30 ng/mL despite documented adherence, increase maintenance to 3,000–6,000 IU daily and evaluate for malabsorption (celiac disease, inflammatory bowel disease, cystic fibrosis) 1, 2
• Once target is achieved, annual monitoring is sufficient 1

Calcium Co-Supplementation

• Ensure adequate calcium intake of 1,000–1,200 mg/day from diet and supplements to optimize bone health and vitamin D efficacy 2

Safety Considerations

• Avoid large annual bolus doses (≥500,000 IU), which increase falls and fractures in older adults 1, 2, 4
• Monthly boluses ≥60,000 IU are also linked to higher fall risk in frail elderly patients 2
• Hypercalcemia typically occurs only when serum 25(OH)D exceeds 200 ng/mL (far above therapeutic targets) 1
• Daily doses up to 4,000 IU are considered safe without medical supervision; therapeutic doses up to 10,000 IU daily may be required in high-risk patients 1, 2

Common Pitfalls to Avoid

• Do not underdose obese patients with standard regimens; they require 2–3× higher doses from the outset 1, 2, 3
• Do not use 800–1,000 IU daily for correction; these doses are for maintenance only and will take many months to normalize deficiency 1
• Do not use calcitriol (activated vitamin D) for nutritional deficiency, as it bypasses physiologic regulation and increases hypercalcemia risk 1
• Do not delay treatment while awaiting repeat testing; a level of 18 ng/mL already warrants immediate repletion 1, 2

Special Clinical Situations

Primary Hyperparathyroidism with Deficiency

• Apply the standard loading regimen despite hypercalcemia; most patients do not experience worsening calcium levels and may show reduced PTH 1
• Monitor serum calcium serially throughout treatment 1

Granulomatous Disorders (Sarcoidosis, Tuberculosis)

• Target a lower 25(OH)D range of 20–30 ng/mL to avoid hypercalcemia from unregulated extrarenal 1,25(OH)₂D production 1
• Monitor both 25(OH)D and serum calcium concurrently during supplementation 1